EWTX- Edgewise Therapeutics, Inc.
Edgewise Therapeutics, Inc. (EWTX) has 15 insiders with recent SEC Form 4 filings, including 3 buys and 9 sells. EWTX is classified in the Biotechnology industry within the Health Care sector.
Insider Ownership
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CFO | 262.5K | $9.27M | - | |
| Other | 105.0K | $3.71M | - | |
| Dir | 45.1K | $1.59M | - | |
| CEO | 38.6K | $1.36M | - | |
| Dir | 30.0K | $1.06M | - |
Activity
Buys and sells only
Transactions
10 filings · page 5
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Feb 9, 2024 | Moore John R45 | General Counsel | Sale+OE | 29,835 | $20.00 | $596,805.46 | -100% | +2.7% | +35.4% | |
| Jan 23, 2024 | Carruthers R Michael48 | Chief Financial Officer | Sale+OE | 90,000 | $15.78 | $1,419,759.00 | -75.6% | -2.5% | +75.5% | |
| Jan 23, 2024 | Thompson Peter A.65 | Director, 10% Owner | Buy | 454,545 | $11.00 | $4,999,995.00 | +3.3% | -2.5% | +75.5% | |
| Jan 23, 2024 | Orbimed Advisors LLC67 | Director, 10% Owner | Buy | 454,545 | $11.00 | $4,999,995.00 | +3.3% | -2.5% | +75.5% | |
| Dec 27, 2023 | Moore John R45 | General Counsel | Sell | 8,497 | $10.50 | $89,218.50 | -100% | +41.7% | +145.1% | |
| Dec 26, 2023 | Russell Alan J77 | Chief Scientific Officer | Sell | 172,585 | $9.33 | $1,610,097.24 | -98.0% | +68.1% | +211.6% | |
| Dec 26, 2023 | Fox Jonathan C | Director | Buy | 10,857 | $9.30 | $100,958.16 | New | +68.1% | +211.6% | |
| May 2, 2023 | Derakhshan Behrad52 | Chief Business Officer | Sale+OE | 1,747 | $8.90 | $15,556.86 | -19.9% | -16.7% | +117.3% | |
| May 2, 2023 | Moore John R45 | General Counsel | Sale+OE | 1,897 | $8.90 | $16,892.60 | -22.4% | -16.7% | +117.3% | |
| May 2, 2023 | Russell Alan J77 | Chief Scientific Officer | Sale+OE | 1,602 | $8.90 | $14,265.65 | -0.9% | -16.7% | +117.3% |